Loading clinical trials...
Loading clinical trials...
Assessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.
To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Coordinating Research Site
San Miguel de Tucumán, Argentina
Coordinating Research Site
São Paulo, Brazil
Coordinating Research Site
Budapest, Hungary
Coordinating Research Site
Cuernavaca, Mexico
Coordinating Research Site
Torun, Poland
Coordinating Research Site
Brăila, Romania
Coordinating Research Site
Moscow, Russia
Coordinating Research Site
Leeds, Yorkshire, United Kingdom
Start Date
November 1, 2007
Primary Completion Date
October 1, 2008
Completion Date
October 1, 2008
Last Updated
January 21, 2016
339
ACTUAL participants
Baminercept alfa (BG9924)
BIOLOGICAL
Lead Sponsor
Biogen
NCT06647069
NCT07484243
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions